| P2093 | author name string | Adam Hutchings | |
| | Richard Dutton | |
| | Carina Schey | |
| | Felix Achana | |
| | Karolina Antonov | |
| P2860 | cites work | Pricing and reimbursement of orphan drugs: the need for more transparency | Q34193502 |
| | Orphan drug: Development trends and strategies | Q34373817 |
| | A comparative study of European rare disease and orphan drug markets | Q37783736 |
| | Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. | Q38680339 |
| | Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. | Q42661063 |
| | Market uptake of orphan drugs--a European analysis | Q44305532 |
| | Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. | Q44708497 |
| | Orphan drug pricing may warrant a competition law investigation | Q82473903 |
| | Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs | Q84788527 |
| P921 | main subject | Sweden | Q34 |
| | orphan drug | Q1367466 |
| P304 | page(s) | 22 | |
| P577 | publication date | 2014-02-13 | |
| P1433 | published in | Orphanet Journal of Rare Diseases | Q15756117 |
| P1476 | title | Estimating the budget impact of orphan drugs in Sweden and France 2013-2020. | |
| P478 | volume | 9 | |